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Abstract 
Introduction: Continuous subcutaneous insulin infusion therapy (CSII) is currently accepted 
as a treatment strategy for type 1 diabetes. Transition from multiple daily injection therapy 
(MDI; including basal-bolus regimens) to CSII is based on expectations of better metabolic 
control and less hypoglycaemic events. Evidence to date has not been always conclusive. 
Areas covered: Evidence for CSII and MDI in terms of glycaemic control, hypoglycaemia and 
psychosocial outcomes are reviewed in adult and paediatric population with type 1 diabetes. 
Findings from studies on threshold-based insulin pump suspension and predictive low 
glucose management are outlined. Limitations of current CSII application and future 
technological developments are discussed. 
Expert opinion: Glycaemic control and quality of life may be improved by CSII compared to 
MDI depending on baseline HbA1c and hypoglycaemia rates. Future studies are expected to 
provide evidence on clinical and cost effectiveness in those who will benefit the most. 
Training, structured education and support are important to benefit from CSII. Novel 
technological approaches linking continuous glucose monitoring and CSII may help to 
mitigate against frequent hypoglycaemia in those at risk. Development of glucose-
responsive automated closed-loop insulin delivery systems may reduce the burden of 
disease management and improve outcomes in type 1 diabetes. 
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Article highlights 
 Continuous subcutaneous insulin infusion (CSII) therapy involves infusion of rapid-
acting insulin analogue according to a pre-programmed basal profile to mimic basal 
insulin secretion, and meal boost insulin to manage post-prandial glucose 
excursions. 
 Glycaemic control is improved by CSII in those suboptimally controlled by multiple 
daily injection (MDI) therapy with a greater treatment at high baseline HbA1c. 
 Most trials were not powered to demonstrate significant differences in hypoglycaemia 
due to low reported baseline rates of hypoglycaemia; however those with the 
greatest hypoglycaemia burden at baseline benefitted significantly from CSII use. 
 Findings from qualitative studies and validated quality of life questionnaires in adults 
and adolescents with type 1 diabetes as well as parents indicate that majority of CSII 
users experienced higher diabetes treatment satisfaction and diabetes-related quality 
of life measures compared to MDI, with very low discontinuation rates of CSII 
therapy. 
 Further innovations in CSII technology are anticipated with the advent of threshold 
suspend features and closed-loop insulin delivery systems, which may further 
improve clinical outcomes. 
 
 
1. Introduction 
 Type 1 diabetes is a chronic autoimmune condition characterised by inflammation 
and destruction of pancreatic B-cell, leading to absolute insulin deficiency and 
hyperglycaemia. The Diabetes Control and Complication Trial (DCCT) and Epidemiology of 
Diabetes Interventions and Complications (EDIC) follow-up study have had major influence 
on clinical practice1, 2. Improvement of glycaemic control by intensive insulin therapy in the 
DCCT significantly reduced the risk of microvascular complications, while EDIC following the 
DCCT cohort demonstrated beneficial effects of intensive insulin therapy which persisted 
17 years later, with reduced risk of cardiovascular events by 42 percent. The intensive 
treatment group in the DCCT received multiple daily insulin injection therapy (MDI) or 
continuous subcutaneous insulin infusion (CSII) therapy. Participants in the DCCT treated 
with CSII achieved and maintained relatively lower glycated haemoglobin (HbA1c) levels 
compared to MDI users. However the rate of severe hypoglycaemia was notably higher in 
the group receiving intensive treatment by around two to three-fold. 
 An important difference to current practise is that modern recommended MDI 
therapy, known as basal-bolus regimen (once or twice daily injections of long-acting insulin 
analogues combined with rapid-acting insulin analogues at mealtimes) are not comparable 
to the older insulin therapy used in the DCCT Modern insulin analogues have faster and less 
variable insulin action profiles compared to older human insulins3. The use of insulin 
analogues have been shown to reduce the relative rate of hypoglycaemia events by 29%, in 
those at highest risk4. Along with comprehensive diabetes self-care and structured 
education, clinical outcomes may therefore differ from earlier studies. As more expensive 
technology becomes integrated with day-to-day healthcare delivery, clinical and cost-
effectiveness needs to be demonstrated. The present article outlines the current evidence of 
CSII and MDI in the adult and paediatric population with type 1 diabetes from the 
perspective of measured glycaemic outcomes and quality of life impact on people with type 1 
diabetes and caregivers. The issues and limitations surrounding CSII application in clinical 
practice are discussed, together with updates on technological developments and 
recommendations for future research to address unanswered questions. 
2. Insulin therapy and delivery methods in clinical practise 
2.1. Multiple daily injections 
 Evidence of intensive insulin therapy in reducing the risk of long-term diabetes 
related complications was first shown in the DCCT, and have subsequently been confirmed 
by other studies5. The MDI regimen of the DCCT control group consisted one or two fixed 
doses of insulin that did not vary with meals, whereas the MDI regimen of the intervention 
group consisted of three or more daily insulin injections adjusted according to self-monitoring 
blood glucose results, dietary intake, and anticipated exercise. As mentioned earlier this has 
been superseded by modern insulin analogues administered in a manner replicating the 
endogenous insulin secretory profile by the healthy pancreas known as the basal-bolus MDI 
regimens. This consists of subcutaneous long-acting or basal insulin to maintain glucose 
homeostasis between meals and normalise glucose levels during fasting period, and quick 
or rapid-acting insulins to provide prandial insulin cover during meals. Basal-bolus regimens  
are now widely advocated by professional clinical bodies and is currently the primary 
strategy for intensive insulin therapy in type 1 diabetes. Subcutaneous insulin preparations 
currently available in clinical practice as part of the basal bolus strategy include soluble 
(regular) human insulin, Neutral Protamine Hagedorn (NPH) insulin and analogue insulins. 
These are subdivided according to duration of action into intermediate/long-acting insulins 
and quick/rapid-acting insulins.  
 NPH is a neutral suspension insulin created by the addition and crystallisation of 
protamine with regular insulin6. Its pharmacokinetic is more in keeping with an intermediate-
acting rather than long-acting insulin. NPH insulin has an onset of action of approximately 
2 to 4 hours. It reaches peak plasma concentration at 4 to 10 hours with duration of action 
up to 10 to 18 hours. It has several disadvantages; its peak action in plasma is often 
associated with nocturnal hypoglycaemia if given at night, and its pharmacokinetics is less 
predictable as subcutaneous absorption of NPH insulin can vary by up to 80%7.  
 The first long-acting insulin analogue introduced in clinical practice was glargine8. In 
glargine, the amino acid of regular insulin, glycine, is substituted for asparagine at position 2. 
It is less soluble at physiologic pH but more soluble at acidic pH, due to the addition of 
arginine residues to the B chain. As glargine precipitates at neutral pH, this leads to slower 
absorption following subcutaneous administration. Its pharmacokinetics is relatively peakless 
compared to NPH insulin, and has a duration of action of approximately 20 to 24 hours9. 
Another long-acting analogue currently being used in clinical practice is insulin detemir, in 
which the amino acid threonine of regular insulin is removed at B30, and fatty acid acylation 
of lysine can be found at B29. This acylation allows the molecule to bind to albumin in 
plasma, thereby prolonging the duration of action of detemir in the systemic circulation10. Its 
half-life is slightly less than glargine (duration of action 18 to 22 hours), thereby necessitating 
twice daily administration by most MDI users. In contrast to glargine it does not form a 
precipitate after subcutaneous injection and has a neutral pH. A recent addition to the basal 
insulin analogue family is degludec, in which the DesB30 human insulin is acylated with 
hexadecandioic acid and forms stable di-hexamers compounds in the presence of phenol 
and zinc. The di-hexamer compounds initially self-associate into depot of multi-hexamer 
chains at the injection site, following subcutaneous injection and dispersion of phenol. The 
diffusion of zinc then causes the multi-hexameric depots to slowly and continuously release 
monomeric compounds of insulin degludec. As a result, insulin degludec has a prolonged 
half-life of 25 hours, and clinical studies have shown a four-fold reduction in day-to-day 
within subject pharmacodynamic variability, compared to insulin glargine11.  
 Example of quick-acting insulin is regular (human) insulin. Regular insulin has an 
onset of action of 30 to 60 minutes, therefore it is advised to be administered 
subcutaneously 30 minutes prior to a meal. Its duration of action after injection is 
approximately 5 to 8 hours. In contrast, rapid-acting insulin which are insulin analogues, 
have faster onset than regular insulin (5 to 15 minutes), with faster peak concentration (0.5 
to 2 hours) and shorter duration of action (3-5 hours)12. Examples of these are insulin aspart, 
lispro and glulisine. Rapid-acting insulin analogues utilise various strategies to reduce insulin 
self-association, leading to earlier hypoglycaemic action compared to regular insulin. Among 
these strategies are introducing charge repulsion (in insulin aspart and glulisine) and stearic 
manipulation (lispro). As these analogues have significantly reduced lag-phase, they can be 
administered subcutaneously immediately with meals therefore allowing greater 
convenience and flexibility for users, althoughoptimal postprandial glucose excursions is 
more likely to be achieved if given 15 minutes before meal13. 
2.2. Continuous subcutaneous insulin infusion therapy  
 CSII was first used in type 1 diabetes in the 1970s14, 15. Early generation CSII devices 
were bulky, unreliable, and delivered a single basal insulin infusion rate, with manually 
triggered boosts or boluses at meal times. Over the years, CSII devices have become 
smaller, more reliable and sophisticated, infusing rapid or quick acting insulin at preselected 
infusion rates with multiple programmable basal profiles to mimic basal insulin secretion. 
Modern CSII device have a number of bolus delivery profile options allowing different 
infusion rate patterns at mealtimes, and integrated on-board calculator which recommend 
insulin bolus dose based on manually entered glucose value, carbohydrate content and 
amount of insulin still active on board16. 
 The advantage of CSII compared to MDI is the planned and immediate adjustments 
that can be made to insulin delivery, in concordance to the varying degree of glycaemia 
levels which may occur throughout the day. Examples include gradual increase in insulin 
infusion rate overnight to address the dawn phenomenon and temporary suspension or 
decrease in insulin infusion rate following increased physical activity or fasting. Conventional 
CSII devices consist of a subcutaneous infusion set (catheter and tubing system), insulin 
reservoir (both replaced every 2 to 3 days) and a portable electromechanical pump. A recent 
innovation in CSII design has been the advent of the patch or "tubing-less" (“tubing-minimal”) 
pump which integrate the infusion set, reservoir unit, pump and automated inserter into a 
single unit which adheres directly to the user's skin, allowing more discretion and freedom of 
movement. 
 The uptake of CSII in clinical practice varies globally, with an estimated 20-25% of 
type 1 diabetes in the US and Norway using CSII, to around 6% in the United Kingdom17, 18. 
This may partly be explained by differences in the provision of service and support cost in 
different countries19. The National Health Service in the United Kingdom provides funding for 
CSII based on recommendations from the National Institute for Health and Clinical 
Excellence (NICE) technology appraisal committee. NICE supports CSII use in adults and 
children ≥12 years of age with type 1 diabetes whose HbA1c remains above 69mmol/mol 
(8.5%) or suffers from recurrent disabling hypoglycaemia during attempts to achieve target 
hbA1c level, despite optimized basal-bolus insulin therapy and best efforts from the patient 
and diabetes team. CSII is recommended in children younger than 12 years and whom MDI 
is considered impractical or inappropriate, with the expectation of reverting to trial of MDI 
between ages 12 to 18 years. NICE also includes provider-specific recommendations such 
as availability of trained specialist team of diabetes specialist nurse, dietitian and 
diabetologist, and user engagement with structured education programmes tailored for CSII 
application.  
 These recommendations are not exclusive to the UK however, and are broadly in line 
with recommendations in other developed countries20. In spite of its potential benefits, CSII 
implementation requires significant commitment and governance due to the underlying risks 
and inherent costs associated with CSII therapy. Examining the evidence for efficacy, safety 
as well as cost-effectiveness of CSII is therefore important to better understand its role and 
benefits in the management of type 1 diabetes. 
3. Evidences from paediatric studies 
3.1. Glycaemic control 
 Two large paediatric diabetes registries, the T1D Registry in the US and the 
Prospective Diabetes Follow-up Registry in Germany and Austria, recently evaluated the 
clinical outcomes of participants under the age of six on CSII and MDI 21. The T1D Registry 
showed that those on CSII had significantly lower average HbA1c levels and were more 
likely to achieve levels less than 7.5%. The Prospective Diabetes Follow-up Registry 
however showed no difference between CSII and MDI. The CSII and MDI groups in the T1D 
Registry had comparable age, BMI z score and total daily insulin dose, whilst CSII users in 
the Prospective Diabetes Follow-up Registry were significantly younger (4.9years vs. 
5.3years, p<0.001). Between the two registries, HbA1c levels discrepancy was greatest 
among MDI than among CSII users. Long-term glycaemic control in 345 children on CSII 
was compared with matched controls on MDI in a single centre observational study22. In 
spite of similar glycaemic control at baseline (HbA1c 8% in both groups), CSII users had 
significantly lower HbA1c throughout the follow-up period compared to the MDI group (mean 
HbA1c difference 0.7% over 5 years). 
 Limited numbers of randomised controlled studies comparing CSII with MDI have 
been performed in the paediatric population. Early randomised controlled studies included 
participants using regular insulin rather than analogues in the CSII group, or early generation 
CSII with limited capacity to alter basal rates and bolus profiles23, 24. This limits the 
generalisability to modern CSII application and practice. A recent meta-analysis evaluated 
randomised controlled studies compared glycaemic control in children and adolescents on 
CSII using rapid-acting analogues, and MDI therapy receiving at least three injections per-
day (with long- and rapid-acting analogues or NPH and regular insulin). The pooled mean 
between-group difference in HbA1c change from baseline was not significantly different 
[mean between group HbA1c difference -0.14% (95% CI -0.48 to 0.20)] and were 
comparable among adolescents > 12 years and children < 12 years25. A criticism of most 
comparative studies and meta-analyses is the inclusion of MDI participants not on 
recommended analogue-based basal-bolus MDI regimen as comparator for CSII (see Table 
1). This may introduce a bias in favour of CSII given the perceived benefits of analogues 
against regular and NPH insulin, and argumentation that analogue-based basal-bolus MDI 
may have comparable glycaemic effects to CSII26. 
3.2. Hypoglycaemia 
 Due to the heterogeneity in reporting and definition of hypoglycaemia, only studies 
with data on severe hypoglycaemia deemed clinically significant (associated with seizure or 
loss of consciousness27) will be stated. In an observational study (n=255), significant 
reduction in the incidence rate of severe hypoglycaemia was shown in CSII users compared 
to MDI users on NPH insulin (31.8/100-patient-years vs. 46.1/100-patient-years, p=0.04)28. 
This was confirmed by another long-term observational study of over 1,160 person-years of 
follow-up, which showed significantly lower rate of severe hypoglycaemia by 30 % in CSII 
user compared MDI (7.2 vs 10.2 per 100 patient-years, p=0.013)22. 
 A meta-analysis of randomised controlled studies in participants on MDI and on CSII 
with insulin analogues reported similar rate of severe hypoglycaemia between the treatment 
group, but had notably wide confidence interval [pooled incidence rate ratio based upon 
events per person-year of 0.99 (95% CI 0.57-1.71)]25. Hypoglycaemia rates are known to 
increase with diabetes duration, and as children generally have shorter duration of diabetes 
than adults the baseline rates of severe hypoglycaemia in this population are considerably 
lower29, 30. Studies included in the meta-analysis were of short duration (less than 6 months) 
with low reported baseline rates of severe hypoglycaemia, and thus were not statistically 
powered to show any significant difference between treatment groups. 
3.3. Quality of life and carers perspective 
 In a prospective pre and post-CSII study involving children and adolescents between 
ages 4 to 16 year, significant increase in diabetes-specific quality of life (QOL) was shown 
across the whole age range following transition to CSII31. Formal comparisons using 
validated measures in six randomised controlled studies found comparable effects on 
general QOL, but CSII users had higher treatment satisfaction measures compared to MDI25. 
The strength of evidences is limited by the different measures used to assess QOL 
outcomes. A comprehensive battery of cognitive tests were applied to children aged 6 to 
16 years in a pilot uncontrolled study at baseline and 6 to 8 weeks after starting CSII32. The 
study reported significant improvements in scores related to perceptual reasoning, selective 
attention, divided attention, cognitive flexibility and working memory. Several small 
randomised controlled studies (n=16-38 participants) which included parental diabetes-
specific QOL scores showed no significant difference between the CSII and MD groups33, 34. 
However in one study an increase in QOL scores in the fathers of the CSII group was 
reported at the 6-month follow-up period 35.  
4. Evidences from adult studies 
4.1. Glycaemic control 
 A Cochrane review of adults with type 1 diabetes showed significant difference in 
HbA1c favouring CSII compared to MDI [weighted mean difference -0.3% (95% CI -0.1 to -
0.4)]24. In a subgroup analysis of medium-term duration studies (one to six months), an 
estimated mean difference of HbA1c of -0.3% (95% CI -0.5 to -0.1) in favour of CSII was 
reported, while in studies longer than 6 months the mean difference was relatively smaller 
(-0.2% [95% CI -0.4 to 0.1]). A recent meta-analysis of randomised controlled studies 
compared CSII using insulin analogues, with MDI36. A significant decrease of HbA1c in 
favour of the CSII group was found (combined mean between group difference -0.30% [95% 
CI -0.58% to -0.02%]). The degree of HbA1c reduction was greater in studies with higher 
HbA1c before CSII initiation. Retrospective analysis of data over 5 years from 272 CSII 
users confirmed that higher HbA1c at start of CSII intervention led to significantly greater 
HbA1c reduction compared to MDI control group (HbA1c reduction of 0.25% [95% CI 0.11 to 
0.39] in participants with baseline HbA1c of 9.0% and BMI of 25 kg/m2)37. 
4.2. Hypoglycaemia 
 Estimated effects on hypoglycaemia may be misleading as most studies were limited 
by participant numbers, duration and frequency of hypoglycaemic episodes, thus statistically 
under-powered. As studies used different scales and definitions for non-severe 
hypoglycaemia, only studies reporting severe hypoglycaemia events will be summarised.   
 A Cochrane review reported lower incidence of severe hypoglycaemia events for 
CSII than MDI, but no meta-analysis of the data was provided24. In a meta-analysis which 
included randomised controlled and before/after studies of participants with significant risk of 
severe hypoglycaemia (initial rate >10 episodes/100 patients years of treatment), those on 
CSII had significantly reduced rate of severe hypoglycaemia compared to MDI (rate ratio of 
2.89 [95% CI 1.45 to 5.76] for RCTs and 4.34 [2.87 to 6.56] for before/after studies)29. Sub-
analysis showed that older participants and those with high frequency of hypoglycaemia at 
baseline had the greatest reduction in severe hypoglycaemia. A meta-analysis of three 
randomised controlled trials comparing CSII using insulin analogues and MDI showed similar 
pooled incidence of severe hypoglycaemia in both groups36. The confidence interval of the 
pooled odds ratio was notably wide [0.74 (95% CI 0.30 to 1.83)], likely due to the small 
number of participants involved in each study (less than 50 in each intervention group) and 
the relatively low rates of severe hypoglycaemia episodes. 
4.3. Quality of life 
 In a randomised controlled study, 50 participants on NPH-based insulin therapy were 
randomised to either lispro-based CSII or lispro and glargine-based MDI for 24 weeks38. 
Diabetes treatment-satisfaction scores were significantly higher in those on CSII. The 5-
Nations trial randomised two hundred and seventy-two participants to CSII or NPH-based 
MDI, in which the CSII group showed significantly higher overall scores for diabetes-specific 
quality of life domains and improvement in mental health perception39. Observational studies 
have similarly reported significant improvements in QOL and treatment satisfaction scores in 
CSII users compared to MDI40, 41. A large case-control study involving 481 CSII and 860 MDI 
users (of which 90% were on glargine-based MDI) from 62 centres confirmed the findings 
from smaller aforementioned studies, with higher diabetes-treatment satisfaction scores as 
well as less fear of hypoglycaemia in CSII users40. 
 Findings from formal validated measures of QOL are in concordance with anecdotal 
evidence observed in usual clinical practice, where most CSII users self-report 
improvements in well-being and mood when transitioned from MDI to CSII. Discontinuation 
rate for CSII, either by choice or otherwise, is reportedly low at most clinical centres42. This 
highlights the potential psychosocial benefits of CSII on the life of those with type 1 diabetes, 
beyond glycaemic control per se.  
 
5. Combining insulin delivery with continuous glucose monitoring: What benefit 
does it add? 
5.1. Continuous glucose monitoring with multiple daily insulin injections 
 
 Real-time continuous glucose monitoring (CGM) allows users to make immediate 
adjustments to their insulin doses, food intake and physical activity by inspecting glucose 
values and trends, and by responding to low and high glucose alarms. The present 
generation of real-time CGM devices utilises a minimally invasive subcutaneously implanted 
needle-type amperometric enzyme electrode to measure interstitial glucose concentration by 
detecting changes in the electric current caused by the enzymatic catalysation of glucose by 
glucose oxidase into hydrogen peroxide, and display new glucose readings every 1 to 5 
minutes43.  
 Comparative analyses of CGM in CSII vs. MDI users are challenging as most studies 
included participants who were on mixed modes of insulin delivery, or were using either real-
time or retrospective CGM (sensor values were masked to participants). The HypoCompass 
study was a 24-week 2 x 2 factorial randomised controlled trial which studied the effects of 
different methods of insulin delivery and glucose monitoring on restoring hypoglycaemia 
awareness and preventing severe hypoglycaemia in participants with hypoglycaemia 
unawareness (Gold score ≥4)44. A sub-analysis comparing CGM-MDI with CGM-CSII 
therapy showed no significant differences at follow-up in biochemical hypoglycaemia 
measures, severe hypoglycaemia episodes, Gold scores and HbA1c. However the analysis 
is weakened by the fact that it did not differentiate between real-time and retrospective CGM 
users in the CSII and MDI groups. No published studies to date have evaluated CGM 
effectiveness with MDI compared to CSII alone.  
5.2. Sensor-augmented pump  
   
 Sensor-augmented pump therapy (SAP) combines real-time CGM with CSII, an 
example of which is the Paradigm Veo (Medtronic Diabetes, Northridge, CA, USA). SAP 
provides users with real-time CGM glucose profile whilst using CSII, making it a useful 
adjunctive tool to aid with retrospective and immediate insulin dose adjustments. Capillary 
glucose measurements are still needed however, to inform any premeal or correction insulin 
boluses. The first large multicentre randomised control trial, the STAR3 study, compared the 
efficacy of SAP with MDI in children and adults45. Subjects on SAP achieved lower HbA1c 
levels (7.5% vs. 8.1%, p<0.001), without increased incidence of hypoglycaemia. 
Improvement in Hba1c was still observed at 18-months follow-up46. In a 26-week study 
comparing SAP with MDI, 87 adults with type 1 diabetes were randomised to either SAP or 
MDI therapy with rapid-acting insulin analogue before meals and long-acting analogues or 
human insulin47. The study showed a significant improvement in the primary outcome (mean 
difference in change in HbA1c after 26 weeks) in favour of SAP (−1.21% (95% confidence 
interval −1.52 to −0.90, P < 0.001). This was achieved without increasing time spent 
hypoglycaemic (CGM values below 4.0 mmol/l), with between-group difference 0.0% (95% 
CI −1.6 to 1.7, P = 0.96).  
 The benefit of adding CGM to CSII was confirmed by a meta-analysis of 
4 randomised controlled studies ranging between 15 weeks to 1 year duration, which 
reported greater reduction in HbA1c for SAP than MDI (combined mean between-group 
difference from baseline -0.68% [95% CI -0.81 to -0.54)36. The authors were unable perform 
a pooled-analysis on the incidence of severe hypoglycaemia due to the different measures 
used by the included studies, and as a result were unable to draw a definitive conclusion. A 
large (n=263) single arm observational study showed that benefits of SAP persisted after 
36 months in terms of HbA1c improvements (decreased from 8.7% to 7.3%, p<0.001), as 
well as treatment satisfaction (improvement in Diabetes Treatment Satisfaction 
Questionnaire score by 9 points, p<0.001)48. 
5.3. Threshold based insulin pump suspension and predictive low glucose 
management  
 SAP with automated insulin suspension represents the first step towards automated 
glucose-responsive insulin delivery systems. The low-glucose suspend (LGS) function 
(Paradigm Veo, Medtronic Diabetes, Northridge, CA, US) allows insulin to be automatically 
suspended for up to 2 hours when sensor glucose falls below a present threshold which is 
determined by the user or healthcare provider, and the hypoglycaemic alarm is not 
acknowledged. There are no published data comparing LGS with MDI, with SAP being the 
active comparator in randomised controlled studies. Post-marketing studies in children and 
adults have reported reduced duration of hypoglycaemia especially in those at greatest risk 
of nocturnal low glucose events49, 50. LGS led to significantly lower rate of second and 
subsequent hypoglycaemia episodes, as well as lower rate of hypoglycaemia events overall. 
In spite of temporary insulin suspension, no evidence of increased ketosis or deterioration in 
HbA1c was observed. The ASPIRE In-Home was a large randomised controlled study which 
evaluated the effects of LGS compared with SAP on HbA1c and nocturnal hypoglycaemia in 
patients at risk with at least two nocturnal hypoglycaemic events during run-in phase51. The 
mean area under the curve for nocturnal hypoglycaemic events was lower by 37.5% 
compared to SAP with comparable HbA1c, thus confirming that LGS can reduce nocturnal 
hypoglycaemia episodes without deterioration of glycaemic control.    
 The predictive low glucose management (PLGM) function of the Medtronic 640G 
CSII device was recently introduced into clinical practise in Europe. In comparison to LGS, 
the hypoglycaemia-prediction algorithm and automatic pump suspension of the PLGM 
system enables insulin delivery to be suspended when hypoglycaemia is predicted and 
insulin delivery automatically restarted when hypoglycaemia risk recedes. Preliminary 
efficacy and safety data in an outpatient setting over 21 nights showed that PLGM reduced 
the proportion of nights with sensor glucose < 3.9 mmol/l by 40%52. Mean overnight glucose 
and morning fasting glucose was reported to be higher than control nights (without PLGM). 
The investigators had to modify the hypoglycaemia-prediction horizon of the algorithm twice 
during the experiment, as pump suspensions occurred frequently leading to elevated 
overnight and morning glycaemia levels. A randomised controlled study evaluated PLGM 
use at home compared to conventional SAP for 42 nights53. The primary endpoint of the 
study, percentage of nights with at least one sensor glucose values < 3.3 mmol/l, was 
approximately halved by PLGM (odds ratio 0.52 [95% CI 0.43-0.64]; P < 0.001). There was 
no difference in overnight sensor glucose levels > 10 mmol/l (57 vs. 59% of nights, p=0.17). 
Current results suggest that use of LGS or PLGM systems do not mitigate against overnight 
or early morning hyperglycaemia.  
6. Limitations and potential solutions 
6.1. Technical and mechanical issues 
 In spite of technological applications in modern CSII devices such as alerts and 
alarms for catheter occlusion or pump failures, CSII users may still be exposed to significant 
and potentially life-threatening conditions if there is lack of vigilance. As there is no 
subcutaneous depot of long-acting insulin during CSII use, interruption of insulin delivery due 
to catheter displacement, catheter/tubing occlusion, battery failure or depletion of insulin 
supply puts the user at risk of diabetic ketoacidosis especially if the interruption is prolonged. 
In a cross-sectional survey of 92 CSII users, nearly half reported some form of pump 
mechanism malfunction54. This includes unintended stoppage of CSII delivery and 
keypad/button problems on the CSII device. Approximately ten percent of those surveyed 
also reported frequent kinking or blockage of infusion set, with an increasing trend 
associated with use of infusion set for longer than 3 days. This highlights the importance of 
user and healthcare provider adherence to proper CSII care and practice guidelines to 
mitigate against potential and relatively common hazards. It also underpins the need for 
regulation of CSII devices to ensure safety standards are met and improve reliability of CSII 
components by manufacturers55. 
6.2. Insulin absorption and pharmacokinetics 
 Subcutaneous absorption and action of insulin via CSII may be altered by local site 
reactions such as inflammation or lipohypertrophy. The quantitative effects of 
lipohypertrophy on changes in insulin pharmacokinetics and pharmacodynamics are still 
poorly understood due to the lack of well-conducted studies in this area56. As a potential 
source of glycaemic variability, this may be of significant clinical concern given that a recent 
survey of CSII users revealed that approximately one in four may have lipohypertrophy54. 
Therefore identifying and avoiding user-driven factors such as repeated injections/infusion 
with needles/catheters at the same body site should be common practise for all CSII users 
and healthcare professionals providing clinical care. Future development of alternative 
infusion delivery mechanism such as intra-dermal microneedle or use of hyaluronidase 
enzyme may accelerate the action and improve the pharmacokinetic consistency of insulin 
analogues used in CSII devices57, 58. 
6.3. Cost-effectiveness 
 The higher cost of CSII compared to MDI presents another limitation to its wider use.  
In the UK, the annualised cost of CSII with a 4-6 year warranty is approximately £1,700 
greater than MDI59. This includes the unit cost of CSII device and consumables related to 
infusion sets and reservoirs; however it does not factor in expenditures on staff and 
education time. Utilising the Centre for Outcomes Research (CORE) model and based on 
assumptions of Hba1c as well as QOL improvements, NICE in the UK deem CSII to be cost-
effective based on a willingness to pay threshold of £20,000 to £30,000 per quality-adjusted 
life year gained42. The estimated cost per quality-adjusted life year improves in favour of 
CSII, if the expected reduction in HbA1c is greater due to expected reduced complications 
risk and health-care costs. The CORE model outcome assumes an average age of 40 years 
at baseline and is greatly influenced by HbA1c reduction rather than indices or impact of 
hypoglycaemia. The existing economic model does not adequately address the paediatric 
population or the individual and societal burden in those at greatest risk of hypoglycaemia, 
such as loss of productivity at work or school and mental health issues related to fear of 
hypoglycaemia. There is therefore a need to re-appraise the analysis of CSII cost-
effectiveness with various stakeholders so that those who may benefit the most from CSII 
are also included. 
7. Expert opinion 
 The ongoing debate of CSII and MDI use in clinical practise has stemmed from the 
growing need by clinicians as well as health care service-providers to ascertain the relative 
benefit of one intervention against the other. Clinicians and people with type 1 diabetes face 
significant challenges when intensifying insulin therapy to reduce the risk of complications. 
The overall evidence currently point towards modest improvements in HbA1c level, severe 
hypoglycaemia rates and QOL measures in favour of CSII compared to MDI, but also that 
CSII may benefit some more than others. An important limitation is that many studies do not 
provide adequate information related to the extent of patient education, and whether self-
management skills provided to both groups were comparable. Some analyses included 
participants not on analogue-based basal-bolus MDI regimens, and information on 
adherence to skills such as carbohydrate counting are lacking. These insufficiencies may 
confound reported outcomes, highlighting the need for well-designed powered studies with 
the comparator following “best clinical practice” and ensuring equal provisions for self-
management skills and education among CSII and MDI users.  
 In reviewing data to address clinical decision-making, few studies and meta-analysis 
currently focus on those with significant and proven clinical need. Analysis should be 
focused on groups with the highest baseline HbA1c and hypoglycaemia burden rather than 
those who are already managing well on MDI, as it is the former rather than latter who may 
benefit the most when transitioned to CSII. Due to the relatively shorter duration of diabetes 
and hypoglycaemia exposure in the paediatric population, there is still a need for well-
conducted statistically powered studies. This is especially true given the benefit of CSII to 
date in terms of lifestyle flexibility and psychosocial impact for parents and children with type 
1 diabetes. Early evidence are also starting to emerge about the potential benefit of CSII in 
lowering cardiovascular mortality compared to MDI60. The exact mechanism however is 
unknown, and the finding remains to be verified and replicated in other cohorts. 
 The importance of self-empowerment and education has to be addressed in any form 
of insulin therapy in type 1 diabetes. Observational studies have shown that those who are 
motivated to invest the time and effort, and are well-educated in their diabetes self-care are 
more likely to achieve better glycaemic control. Family-centred, structured education 
programme in specialist centres and routine clinical care among the paediatric population 
have shown more personal engagement by family members around diabetes-related tasks, 
however the improvements in HbA1c was relatively modest 61, 62. In addition, ensuring 
optimal training and education to families and those needing it the most can be challenging, 
as reported by a qualitative study evaluating the feasibility of an education programme 
carried out across paediatric clinics in the UK63. Among the reported barriers were 
organisational difficulties and time-commitment by staff members, reflecting real-world 
feasibility issues. Adult diabetes education courses such as Dose Adjusted for Normal 
Eating (DAFNE) in the UK which are delivered by trained diabetes educators, have shown 
benefits in glycaemic control and quality of life64, 65. Optimisation of MDI therapy using 
programmes such as DAFNE should therefore be offered to all adults with type 1 diabetes.  
 The support and engagement to optimise their MDI therapy should be continuous 
during the course of their care with both parties fully involved, rather than to be used as a 
short-term bridge before CSII initiation. Transitioning to CSII, users and healthcare providers 
should acknowledge that realising the full potential of CSII involves similar if not more 
commitment to self-care, as well as a good knowledge base of insulin therapy. Trained pump 
educators should be available to provide support after transitioning to CSII, for example in 
downloading and reviewing glucose/insulin data from CSII devices, and helping make 
appropriate adjustments to insulin delivery settings. Future studies determining the benefits 
of CSII over MDI following exposure to structured educational programmes should ensure 
that such programmes cater for comprehensive CSII training and re-training.  
 Further innovation in diabetes technology is anticipated. The advent of SAP shows 
that integration of CSII with real-time CGM may provide additional benefit to glycaemic 
control in both adults and youth with type 1 diabetes, provided CGM use is high and 
consistent. Automated insulin delivery suspension at low or predicted low CGM levels may 
confer additional protection against hypoglycaemia, especially in those at greatest risk. 
Rapid progress in also being made in the development of closed-loop insulin delivery 
systems also known as the “artificial pancreas”, which uses a control algorithm that 
automatically smoothly modulates (increases and decreases) CSII insulin delivery based on 
real-time CGM values66. Results from closed-loop clinical studies conducted in controlled 
research facility and unsupervised home settings have been promising67-69. Recently a three 
month application of closed-loop insulin delivery in real-world free-living conditions showed 
significant improvements in glycaemic control and reduction of hypoglycaemia events 
compared to optimised SAP70.Larger and longer multicentre studies are being planned, and 
closed-loop insulin delivery systems may act as a ‘bridge’ until a biological cure for type 1 
diabetes is found. 
 Advances in diabetes treatment and technology have the potential to reduce the 
considerable demands type 1 diabetes management has on people with type 1 diabetes and 
their caregivers. In those unable to achieve their glycaemic goal in spite of sufficient support, 
CSII may benefit them whilst potentially improving their quality of life. Well-conducted studies 
in those who would likely benefit from CSII most are still needed to provide further guidance 
and information to healthcare providers, and evidence for its use in clinical practice. 
Table 1. Summary of studies comparing CSII with analogue- or NPH-based basal-bolus MDI regimens with HbA1c and hypoglycaemia endpoints. 
Reference Population 
Study 
design 
CSII 
intervention 
MDI 
regimen 
Number of 
participants 
Study 
duration 
Main findings 
DeVries Adults Randomised 
parallel design 
CSII therapy 
with rapid- 
acting insulin 
analogue 
NPH-based 
basal insulin 
plus mealtime 
aspart 
 
62 16 weeks Mean HbA1c was 0.84% (95% CI -1.31 to -0.36) lower in 
the CSII group compared with the MDI group (P = 0.002). 
Number of patients with severe hypoglycaemia episodes 
was similar in either group. 
Hoogma Adults Randomised 
parallel design 
CSII therapy 
with rapid- 
acting insulin 
analogue 
NPH-based 
basal insulin 
plus mealtime 
lispro 
 
272 6 months Hba1c values were similar at baseline (8.3±1.1 vs. 
8.2±1.4%), and reduced significantly in the CSII compared 
to MDI group (7.45 vs. 7.67%, P < 0.001). CSII users had 
significantly fewer severe hypoglycaemia events (0.5 vs. 
0.2 events per patient year, P < 0.001) 
 
Skogsberg Paediatrics Randomised 
parallel design 
CSII therapy 
with rapid- 
acting insulin 
analogue 
NPH-based 
basal insulin 
plus mealtime 
aspart 
72 24 months HbA1c was similar at baseline (8.2 ± 0.4% in the CSII 
group and 8.4 ± 0.5% in the MDI group, p = 0.57). There 
was no significant difference in HbA1c after 24 months( 
6.5 ± 0.4 vs. 6.7 ± 0.5%, p = 0.66). There were no 
significant differences in severe hypoglycaemia between 
the two groups. 
 
Bolli Adults Randomised 
parallel design 
CSII therapy 
with rapid- 
acting insulin 
analogue 
Analogue-
based basal 
bolus therapy 
 
50 24 weeks Mean A1C reduction was similar in the two groups (CSII -
0.7 +/- 0.7%; MDI -0.6 +/- 0.8%) with a baseline-adjusted 
difference of -0.1% (95% CI -0.5 to 0.3). The incidence of 
overall hypoglycaemia events was similar in either group. 
  
Doyle Paediatrics Randomised 
parallel design 
CSII therapy 
with rapid- 
acting insulin 
analogue 
Analogue-
based basal 
bolus therapy 
32 16 weeks HbA1c levels in the CSII group significantly decreased from 
8.1±1.2% to 7.2 ± 1.0% at 16 weeks (P < 0.02 vs. baseline 
and P < 0.05 vs. MDI group). No significant difference in 
HbA1c was observed in the MDI group. Five episodes of 
severe hypoglycaemia occurred in the MDI group, and 
none in the CSII group. 
 
Bergenstal Adults and 
paediatrics 
Randomised 
parallel design 
Sensor-
augmented 
pump therapy 
with rapid-acting 
insulin analogue 
Analogue-
based basal 
bolus therapy 
495 12 months Baseline mean HbA1c level (8.3% in both groups) 
decreased to 7.5% in the sensor-augmented pump therapy 
group (- 0.8±0.8 percentage points), compared with 8.1% 
in the injection-therapy group (-0.2±0.9 percentage points). 
Between-group difference was -0.6 percentage points 
(95% confidence interval CI –0.7 to –0.4; P<0.001). Rate of 
severe hypoglycaemia did not differ between the tow two 
groups. 
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